tbuckley/cabot-search huggingface dataset:
Abstract 23233: Asymptomatic Cerebral Infarction During Catheter Ablation Of Atrial Fibrillation Comparing Uninterrupted Rivaroxaban And Warfarin (ASCERTAIN Study)
Authors: Seiji Takatsuki, Takehiro Kimura, Kazuaki Nakajima, Shin Kashimura, Akira Kunitomi, Yoshiki Katsumata, Takahiko Nishiyama, Kohei Inagawa, Yukinori Ikegami, Nobuhiro Nishiyama, Yoshiyasu Aizawa, Kojiro Tanimoto, Keiichi Fukuda
Journal: Circulation (2016)

Introduction: The incidence of asymptomatic cerebral infarctions (ACIs) during catheter ablation (CA) of atrial fibrillation (AF) is reported to be 10-30%, which could be affected by periprocedural...
Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma
Authors: Stanley R. Hamilton
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT
Authors: Nathan Robison, Jasmine Pauly, Jemily Malvar, Mariella Filbin, Rebecca Loret de Mola, Kathleen Dorris, Anne Bendel, Daniel Bowers, Miriam Bornhorst, Karen Gauvain, Sarah Leary, Tobey MacDonald, Sharon Gardner, Alyssa Reddy, Patricia Diaz, Yi Juin Tan, Claire Sinai, Tom Davidson, Nicole Ullrich, Ashley Margol, Girish Dhall, Mark Borchert, Keith Ligon, Richard Sposto, Mark Kieran
Journal: Neuro-Oncology (2017)
P3.02-046 EGFR-Grb2-GEP100 Complex Promoted Its Invasive and Metastatic Potential via Arf6 Pathway in Lung Adenocarcinoma
Authors: T. Menju, H. Ishikawa, R. Miyata, S. Nishikawa, K. Takahashi, M. Hamaji, H. Motoyama, A. Aoyama, C. Fengshi, T. Sato, M. Sonobe, H. Date
Journal: Journal of Thoracic Oncology (2017)
P3.02-010 Significant Increase of Blood Extracellular Vesicles in Pulmonary Vein as Potential Prognostic Biomarker for Lung Cancer Patients
Authors: B.H. Choi, Y.H. Quan, J. Rho, R. Xu, Y. Choi, J. Park, Y.B. Choy, Y.H. Choi, H.K. Kim
Journal: Journal of Thoracic Oncology (2017)
Global infection prevention and control priorities 2018–22: a call for action
Authors: Benedetta Allegranzi, Claire Kilpatrick, Julie Storr, Edward Kelley, Benjamin J Park, Liam Donaldson
Journal: The Lancet Global Health (2017)

The Ebola virus disease outbreak in west Africa and the rapid spread of other emerging viruses, such as the severe acute respiratory syndrome or the Middle East respiratory syndrome coronaviruses, showed how limited or non-existent infection prevention and control (IPC) programmes, combined with an inadequate water supply, poor sanitation, and a weak hygiene infrastructure in health facilities, can threaten global health security. In such outbreaks, instead of serving as points where disease was controlled, health-care facilities became dangerous places for outbreak amplification among staff and patients and transmission back to communities.
Un sistema nacional de vigilancia sindrómica en Inglaterra y Gales basado en una línea de alerta telefónica
Authors: G E Smith, D L Cooper, P Loveridge, F Chinemana, E Gerard, N Verlander
Journal: Eurosurveillance (2006)

Los datos de atencion primaria recogidos de forma rutinaria son un medio de vigilar un gran numero de sindromes que pueden ser senales de alertas precoces de amenazas para la salud publica. El del Reino Unido, un sistema nacional de vigilancia sindromica, operado conjuntamente por el Instituto ingles de salud publica (Health Protection Agency, HPA) y NHS Direct (un numero nacional de ayuda a los pacientes) analiza los sintomas comunicados a NHS Direct. Los datos de 11 sintomas/ sindromes son enviados por correo electronico por los 22 centros de llamadas de NHS Direct en Inglaterra y Gales y diariamente analizados por el HPA. Los excesos de llamadas estadisticamente significativos se identifican automaticamente y son evaluados por un equipo multidisciplinario. El sistema de vigilancia subrayo varios aumentos subitos de los sindromes relatados a NHS Direct, pero no se detecto ninguna prueba de un ataque biologico o quimico. Sin embargo, este sistema constituye una herramienta de alerta precoz y de seguimiento de los aumentos de morbilidad en la comunidad (por ejemplo, los sindromes gripales, las ondas de calor) ; tambien permite tranquilizar a la poblacion en periodos de percepcion de riesgos importantes (como tras las bombas del 7 de julio de 2005 en Londres, o el incendio del deposito de combustible de Buncefield en diciembre de 2005) ; finalmente dicho sistema proporciona datos de vigilancia rapidos para los planes de preparacion de pandemia gripal y para la modelizacion epidemica.
OA 02.06 Radioimmunotherapy Combining CTLA-4 Blockade or Low-Dose Cyclophosphamide with Local Radiation in Murine Malignant Mesothelioma
Authors: M. Kohno, L. Wu, L. De La Maza, Z. Yun, M. Chan, Y. Yao, Y. Zhao, M. De Perrot
Journal: Journal of Thoracic Oncology (2017)
Abstract 15448: Dietary Patterns and Incident Heart Failure in Adults With No Known Coronary Disease or Heart Failure: The REGARDS Cohort
Authors: Kyla M Lara, Emily B Levitan, Orlando M Gutierrez, James M Shikany, Monika M Safford, Suzanne E Judd, Robert S Rosenson
Journal: Circulation (2017)

Introduction: The relationship between dietary patterns and incident heart failure (HF) has not been well established. Aim: Investigate dietary patterns and the association with incident HF. Method...
Abstract 15530: SMC-specific Impairment of PLA2g6-dependent SOCE as a New Mechanism of Protection Against Arterial Stiffening
Authors: Joon W Shim, Francesca Seta, Victoria M Bolotina
Journal: Circulation (2017)

Introduction: Aging or high fat high sucrose (HFHS) diet-induced arterial stiffening is an independent risk factor of cardiovascular disease. However, the mechanism or specific role of vascular smo...
EXTH-46. A PRECISION MEDICINE APPROACH TO TARGET EGFRvIII IN GBM: OSIMERTINIB (AZD9291) INHIBITS THE GROWTH OF EGFRvIII-POSITIVE GLIOBLASTOMA STEM CELLS AND INCREASES SURVIVAL OF MICE BEARING INTRACRANIAL EGFRvIII-POSITIVE GBM
Authors: Madan Kwatra, Cory Nanni, Callie Roberts, Shawn Kwatra, Mark R Gilbert, Glenn J Lesser
Journal: Neuro-Oncology (2017)

Attempts to target EGFRvIII, which is present in over 20% of GBMs, with EGFR-tyrosine kinase inhibitors (EGFR-TKI) and vaccines have been unsuccessful. This failure appears to be due to two main reasons: 1) the selected EGFR-TKI did not penetrate the brain well; and 2) the heterogeneity of EGFRvIII was not addressed. Here we present data on osimertinib (AZD9291), a third generation irreversible EGFR-TKI, that was developed to specifically block the EGFRT790M mutation that leads to drug resistance in lung cancer patients treated with an earlier generation EGFR-TKI. Our initial studies found that osimertinib also potently inhibits EGFRvIII (IC50<50 nM) and is highly brain-penetrant, with a brain/plasma ratio >10. Therefore, we studied osimertinib's ability to inhibit EGFRvIII in preclinical models of GBM. For in vitro studies, we examined the effect of osimertinib on EGFRvIII biochemistry using EGFRvIII-positive GBM stem cells (GSCs). For in vivo studies, immunocompromised mice were implanted intracranially with EGFRvIII-positive GSCs. Three days after implantation, the animals were given 25 mg/kg of osimertinib twice a day; this is a clinically relevant dose. Our findings are as follows: 1) osimertinib not only inhibits EGFRvIII tyroinse kinase activity with high affinity but also blocks its downstream signaling in EGFRvIII-positive GSCs; 2) osimertinib increases the survival of mice bearing intracranial EGFRvIII-positive GBM. The median survival of mice treated with vehicle alone was 28.5 days whereas the median survival of mice treated with AZD9291 was 42 days (p<0.001); an increase in survival of 47%. In contrast, treatment with lapatinib, a traditional EGFR-TKI, did not result in increased survival. These results indicate that osimertinib may be effective in increasing the survival of a subset of patients with EGFRvIII-positive GBM. Clinical studies to demonstrate the efficacy of osimertinib in EGFRvIII-positive GBM patients will commence soon.
Blood stream infection in cancer patients—device management and epidemiology: the BSIDE study
Authors: F. Cortiula, D. Basile, L. Gerratana, M. Bonotto, E. Ongaro, S.K. Garattini, V. Fanotto, M. Cattaneo, V.J. Andreotti, A. Parnofiello, R. Cocconi, D. Pecori, G.G. Cardellino, M. Casagrande, P. Ermacora, M. Giovannoni, D. Iacono, F. Puglisi, G. Aprile, N. Pella, G. Fasola
Journal: Annals of Oncology (2017)
P1.01-040 Clinical Utility of Plasma-Based NGS for Advanced-Stage NSCLC Patients with Insufficient or Unavailable Tumor Tissue
Authors: J. Zugazagoitia, A. Gómez Rueda, S. Ponce, I. Ramos, C. Camps, D. Isla, Ó. Juan, R. García Campelo, J. De Castro, M. Trigo, E. Jantus-Lewintre, M. Palka, L. Paz-Ares, P. Garrido
Journal: Journal of Thoracic Oncology (2017)
Locoregional treatments and sites of metastatic involvement in metastatic gastric cancer patients: do they influence survival?
Authors: L. Cantini, L. Cantini, R. Giampieri, M. Palladino, M. Del Prete, A. Bittoni, E. Giglio, T. Meletani, G.M. Baleani, E. Maccaroni, M. Di Pietro Paolo, R. Berardi
Journal: Annals of Oncology (2017)
MA 08.11 Do Patients Treated with Chemotherapy for Advanced NSCLC Regret Having Received Treatment? A Prospective Evaluation in 164 Patients
Authors: P. Hollen, R. Gralla, B. Coyne, R. Hall, R. Genzler, H. Cheng, G. Weiss, J. Gildersleeve, I. Hinton, J. Crawford, L. Rosen, M. Lesser
Journal: Journal of Thoracic Oncology (2017)
Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
Authors: Marc Arbyn, Charles W E Redman, Freija Verdoodt, Maria Kyrgiou, Menelaos Tzafetas, Sadaf Ghaem-Maghami, Karl-Ulrich Petry, Simon Leeson, Christine Bergeron, Pekka Nieminen, Jean Gondry, Olaf Reich, Esther L Moss
Journal: The Lancet Oncology (2017)
Surgery and the elderly: when an apparent overtreatment becomes safe and effective
Authors: P. Mordenti, S. Lucchini, E. Zaffignani, D.L. Capuano, E. Palermo, P. Scagnelli, L. Zanlari, R. Achilli, M.L. Galli, E. Marazzi, M. Mazzocchi, S. Gandolfi, B. Granelli, M. Sfulcini, D. Terzoni, G. Zanatta, L. Cavanna
Journal: Annals of Oncology (2017)
P1.07-014 Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers
Authors: T. Akamine, K. Takada, G. Toyokawa, F. Kinoshita, T. Matsubara, Y. Kozuma, N. Haratake, S. Takamori, F. Hirai, T. Tagawa, T. Okamoto, Y. Yoneshima, I. Okamoto, M. Shimokawa, Y. Oda, Y. Nakanishi, Y. Maehara
Journal: Journal of Thoracic Oncology (2017)
HOUT-04. COMPARISON OF ENDOSCOPIC AND OPEN SKULL BASE SURGICAL RESECTION OF HIGH-GRADE ESTHESIONEUROBLASTOMA OVER THE LAST DECADE: THE UC IRVINE EXPERIENCE
Authors: Ronald Sahyouni, Frank PK Hsu, Gilbert Cadena
Journal: Neuro-Oncology (2017)

Esthesioneuroblastoma (ENB) is a rare malignant neoplasm that can be treated with open or endoscopic skull base approaches. We compared both approaches and present our outcome data. A retrospective review from 2007 through 2017 yielded 12 ENB patients. Kadish and TNM stage, Hyams grade, Ki-67, adjuvant chemoradiation, and resection type were correlated with survival, recurrence and surgical morbidity. Mean age was 61.1 ± 9.4 years, 25% of patients were female. Median follow-up was 4.6 years. 8%, 67%, and 25% of patients were Kadish stage B, C, and D, respectively. Hyams grade III and IV tumors were equally distributed among both groups. Eleven patients underwent surgical resection; five underwent endoscopic, five underwent open, and one patient underwent combined resection. In the endoscopic group, four patients were Kadish stage C, compared to three with Kadish stage D in the open group. TNM in the open group was uniformly T4N1M0, while the endoscopic group was T1-2N0M0. Percentage of tumors with Ki-67 >15% was equal in both groups. Positive margins were identified in 60% of endoscopic resections and 20% of open resections. Five patients had postoperative complications, including 20% of endoscopic patients and 60% of open patients. Eleven patients received radiotherapy, and 67% of patients received chemotherapy that included cisplatin/etoposide. 50% of patients were disease-free at last follow up. 80% of patients who had open resection experienced local recurrence, compared to 0% in the endoscopic group. Median time to recurrence in the open group was 4 years, and 4.4 years across all patients, with 60% of recurrences occurring >5 years from the initial surgery. Our data suggests that endoscopic resection of high grade ENB (Kadish C) with adjuvant chemoradiation can have favorable results with fewer postoperative complications compared with open resection.
CSIG-16. UNDERSTANDING THE MECHANISM OF RIOK2 FUNCTION IN GLIOBLASTOMA
Authors: Alexander Chen, Renee Read
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM), a tumor derived from glia and glial progenitor cells, is the most aggressive and prevalent form of primary brain cancer and is incurable. Amplification, mutation, and/or overexpression of the EGFR receptor tyrosine kinase and activating mutations in components of the PI3K pathway are common in GBM tumors, although the pathways that act downstream of EGFR and PI3K to drive tumorigenesis remain poorly understood. To better understand the underlying biology of tumorigenesis, we use a Drosophila melanogaster GBM model in which malignant neoplastic tumors arise from glial progenitor cells overexpressing activated oncogenic versions of EGFR and PI3K. This Drosophila model was used in kinome-wide genetic screens that identified Right-Open-Reading-Frame-2 (RIOK2), an atypical serine-threonine kinase, as a possible driver of EGFR-PI3K-dependent GBM. Subsequent studies in patient-derived GBM cell cultures suggest that RIOK2 promotes GBM cell proliferation and survival in response to oncogenic EGFR and PI3K signaling, and that, interestingly, these effects are dependent on RIOK2 catalytic kinase activity. To elucidate downstream targets of RIOK2, we conducted preliminary immunoprecipitation experiments of RIOK2 from patient-derived GBM cell cultures coupled with proteomics and identified several novel RNA-binding proteins (RBPs) as binding partners and potential substrates of RIOK2. Subsequent experiments using our Drosophila GBM model show that RBP knock-down drastically reduced aberrant glial cell proliferation and invasion, similar to RIOK2 knock-down. RBPs are involved in stabilizing and promoting the translation of their target mRNAs. Based on our preliminary results, we hypothesize that RIOK2 drives tumorigenesis by modulating the activity of RBPs, and that this promotes the translation of RBP target mRNAs to drive tumor cell proliferation and survival.
Abstract 135: Pim-1 Modification Reverses Senescent Phenotype Of Hcpcs From Patients With Heart Disease
Authors: Sadia Mohsin, Mohsin Khan, Monique Alkatib, Jonathan Nguyen, Kathleen Wallach, Mark A Sussman
Journal: Circulation Research (2013)

Rationale: Adoptive transfer of human cardiac progenitor cells (hCPCs) can repair damaged myocardium and improve function in a pathologically challenged heart. hCPC’s isolated from multiple patients exhibit differences in growth kinetics, expression of cell cycle regulators and telomere length suggesting hCPCs with slow growth kinetics may compromise effective regeneration of damaged or aged myocardium. There is a dire need to reverse the senescent phenotype of hCPCs exhibiting slow growth kinetics to improve the outcome of regenerative therapy. Objective: Demonstrate that Pim-1 engineering reverses the senescent phenotype of human cardiac progenitor cells (hCPCs) with slow growth kinetics by increasing their telomere length and decreasing population doubling time and cell cycle inhibitors. Methods and Results: hCPCs positive for stem cell marker c-kit were isolated from heart biopsy samples from patients undergoing Left Ventricular Assist Device (LVAD) implantation. hCPCs isolated from multiple patients were characterized for growth kinetics, telomere length, expression of cell cycling regulators. hCPCs with slow growth kinetics exhibit decreased telomere length concomitant with increased population doubling time and upregulation of senescent markers compared to hCPCs with fast growth kinetics. hCPCs were engineered to express Pim-1-GFP (hCPCeP), a fused GFP version of the kinase by using a lentivirus expression system. Cell cycling measured by population doubling time was decreased in hCPCeP. Similarly, telomere lengths in hCPCeP were significantly increased relative to control hCPCs expressing GFP (hCPCe). Similarly, the expression cell cycling inhibitors including p16 and p53 is down regulated indicative of reversal of senescent characteristics. Conclusion: Ex vivo gene delivery of Pim-1 in hCPCS enhances telomere length and decreases population-doubling time and senescent phenotype. These changes are more significant and distinct in hCPCs with slow growth kinetics. Pim-1 modification of hCPCs with slow growth kinetics from patients with heart failure can augments their ability to regenerate damaged myocardium and address current limitations associated with senescent phenotype of aged hCPCs.
MA 06.01 Cancer Testis Antigens and Mutational Load in Relation to the Immune Landscape of Non-Small Cell Lung Cancer
Authors: M. Backman, P. Kurppa, D. Djureinovic, L. La Fleur, J. Persson, J. Mattsson, J. Botling, E. Branden, H. Koyi, F. Ponten, P. Micke
Journal: Journal of Thoracic Oncology (2017)
P2.14-012 Clinical Outcomes of the Largest UK Cohort of Cyberknife-Delivered Stereotactic Ablative Body Radiotherapy (SABR) for Primary Lung Cancers
Authors: S. Mascall, B. Allos, M. Vreugdenhil, S. Watkins, R. Stevenson, Q. Ghafoor
Journal: Journal of Thoracic Oncology (2017)
Vigilancia de infecciones de transmisión sexual en Escocia
Authors: A Noone, J Chalmers, H Young
Journal: Eurosurveillance (1998)

La vigilancia de las infecciones de transmision sexual (ITS) permite la determinacion de prioridades en la planificacion de los servicios de prevencion y tratamiento, la evaluacion de las intervenciones y la formulacion de hipotesis de investigacion (1).
Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis
Authors: Cyrielle Caussy, Mosab H. Alquiraish, Phirum Nguyen, Carolyn Hernandez, Sandra Cepin, Lynda E. Fortney, Veeral Ajmera, Ricki Bettencourt, Summer Collier, Jonathan Hooker, Ethan Sy, Emily Rizo, Lisa Richards, Claude B. Sirlin, Rohit Loomba
Journal: Hepatology (2017)

The optimal threshold of controlled attenuation parameter (CAP) for the detection of hepatic steatosis using both M and XL probe is unknown in nonalcoholic fatty liver disease (NAFLD). Magnetic resonance imaging proton density fat fraction (MRI‐PDFF) is an accurate and precise method of detecting the presence of hepatic steatosis that is superior to CAP. Thus, the aim of this study was to evaluate the diagnostic accuracy and optimal threshold of CAP for the detection of hepatic steatosis as defined by MRI‐PDFF ≥ 5%. This prospective cross‐sectional study included 119 adults (59% women) with and without NAFLD who underwent MRI‐PDFF and CAP using either M or XL probe when indicated within a 6‐month period at the NAFLD Research Center, University of California, San Diego. The mean ( ± standard deviation) age and body mass index were 52.4 (±15.2) years and 29.9 (±5.5) kg/m2, respectively. The prevalence of NAFLD (MRI‐PDFF ≥ 5%) and MRI‐PDFF ≥ 10% was 70.6% and 47.1%, respectively. The area under the receiver operating characteristic (AUROC) of CAP for the detection of MRI‐PDFF ≥ 5% was 0.80 (95% confidence interval [CI], 0.70‐0.90) at the cut‐point of 288 dB/m and of MRI‐PDFF ≥ 10% was 0.87 (95% CI, 0.80‐0.94) at the cut‐point of 306 dB/m. When stratified by the interquartile range (IQR) of CAP, we observed that an IQR below the median (30 dB/m) had a robust AUROC compared with an IQR above the median (0.92 [95% CI, 0.85‐1.00] versus 0.70 [95% CI, 0.56‐0.85]; P = 0.0117), and these differences were statistically and clinically significant. Conclusion: The cut‐point of CAP for presence of hepatic steatosis (MRI‐PDFF ≥ 5%) was 288 dB/m. The diagnostic accuracy of CAP for the detection of hepatic steatosis is more reliable when the IQR of CAP is <30 dB/m. These data have implications for the clinical use of CAP in the assessment of NAFLD. (Hepatology 2018;67:1348‐1359)
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non–Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
Authors: Akshima Sharma, Anant Mohan, Ashu Seith Bhalla, Mehar Chand Sharma, Sreenivas Vishnubhatla, Chandan J. Das, Anil Kumar Pandey, Chandra Sekhar Bal, Chetan D. Patel, Punit Sharma, Krishan Kant Agarwal, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2017)

The aim of this study was to prospectively evaluate the role of various quantitative and semiquantitative metabolic parameters derived from dynamic and static baseline F-FDG PET/CT in prediction of overall survival (OS) in non-small cell lung cancer (NSCLC) patients who were planned to undergo platinum-based chemotherapy.Sixty patients (51 male and 9 female patients) with biopsy-proven NSCLC and mean age 59.55 ± 10.06 years who were planned to undergo platinum-based chemotherapy were enrolled in the study. Each patient underwent a baseline regional dynamic and a static whole-body F-FDG PET/CT after injecting 0.21 mCi/kg (5.18-7.77 MBq/kg) of F-FDG intravenously. Two dynamic PET/CT parameters, that is, net influx rate constant and glucose metabolic rate at 30 and 60 minutes, were evaluated. In addition, whole-body PET/CT parameters, that is, SUVmax, average SUV, tumor-to-background ratio, metabolic tumor volume (MTV), total lesion glycolysis (TLG) of the primary tumor, and MTV and TLG of whole-body tumor lesions, were evaluated. Best possible cutoffs for all parameters were calculated using receiver operating characteristic curve analysis. Survival analysis was performed using log-rank test, Kaplan-Meier curves, and Cox proportional hazards model to determine the prognostic markers for OS.The median follow-up period was 4.4 months (range, 8 days to 15.9 months). In univariate analysis, the 4 static whole-body PET/CT parameters, that is, MTV, TLG, and MTV and TLG of whole-body tumor lesions, were found to be significantly associated with OS with cutoff values of 120, 800, 160, and 1350 cm and hazard ratios of 3.64 (P = 0.001), 3.35 (P = 0.002), 2.51 (P = 0.019), and 2.69 (P = 0.008), respectively. In multivariate survival analysis, MTV was found to be an independent prognostic marker for OS.Baseline MTV and TLG evaluated from primary tumor as well as the whole-body tumor lesions are reliable prognostic markers of OS in NSCLC patients undergoing platinum-based chemotherapy. However, other baseline whole-body PET/CT parameters (SUVmax, average SUV, and tumor-to-background ratio) and dynamic PET/CT parameters (net influx rate constant, glucose metabolic rate) have no prognostic value in these patients.